osteogenic

YGFGG, C-terminal pentapeptide fragment of the osteogenic growth peptide (OGP), (H-8640), showed the full spectrum of OGP-like bioactivities. It has attracted considerable interest as bone anabolic agent and hematopoietic stimulator.

Osteogenic Growth Peptide, OGP acetate is a short, naturally occurring 14-mer growth factor peptide found in serum at μM concentrations. Osteogenic growth peptide OGP is a key factor in the mechanism of the systemic osteogenic response to local bone marro

Osteogenic Growth Peptide (10-14) acetate (Osteogenic Growth Peptide) is a Src inhibitor and an effective mitogen and stimulator of osteogenesis and hematopoiesis. Osteogenic Growth Peptide (10-14) acetate is responsible for the binding to the OGP receptor and activates an intracell

Osteogenic Growth Peptide (OGP) is a short, naturally occurring 14-mer growth factor peptide found in serum at μM concentrations and is a key factor in the systemic osteogenic response to local bone marrow injury.

Preptin, an osteogenic peptide derived from pancreatic beta-cells, spans amino acids Asp 69 to Leu 102 within pro-IGF-II [1].

Peptide K is a self-assembling peptide fiber used for fabricating fibrous nanocomposite hydrogels. These hydrogels possess a dynamic network adaptable to cells, enhancing cell-matrix and cell-cell interactions. Consequently, they significantly promote the mechanotransduction, metabolic energy, and osteogenic function of encapsulated stem cells.

The compound AVSEHQLLHDKGKSIQDLRRRFFLHHLI-{Aib}-EIHTAYRFGG facilitates bone ossification and has potential applications in the study of conditions associated with osteogenic insufficiency or diminished bone mineral density (BMD), including osteoporosis [1].

VnP-16, a synthetic peptide fragment mirroring amino acids 270-281 of vitronectin (a multifunctional glycoprotein involved in cell attachment, migration, and spreading), promotes attachment and spreading of isolated human osteogenic cells. This effect is reversible with β1 integrin siRNA knockdown when VnP-16 is applied at 9.1 µg/cm2 on cell plates. The compound enhances osteogenesis in human skin-derived mesenchymal precursors and MC3T3-E1 mouse calvarial osteoblast precursors. Furthermore, in vivo studies show VnP-16 mitigates IL-1α-induced bone loss, reduces calvarial osteoclast numbers in mice, increases bone mineral density, and lessens trabecular bone loss in a mouse model of ovariectomy-induced bone loss.

BMP2-derived peptide, encompassing amino acids 73 to 92 of BMP-2, induces osteogenic differentiation in bone marrow stromal cells (BMSCs) and augments bone regeneration [1].